Grand Park Law Group represented Alnylam Pharmaceuticals, Inc. in its $2.8 billion partnership with Roche to develop and commercialize Alnylam’s investigational RNA interference therapeutic zilebesiran for hypertension.
Grand Park Law Group, A.P.C.